AllSci News
QuantX Biosciences secures USD 85m in Series B for computational drug discovery platform
Princeton, NJ-based QuantX Biosciences has closed an oversubscribed USD 85 million Series B financing round, signaling strong investor confidence in the company’s…
EQT leads USD 39m Series A for Aerska’s RNA brain delivery platform
Ireland-based biotechnology startup Aerska has secured USD 39 million in Series A financing to advance its pioneering brain shuttle technology for delivering…
Iambic, Takeda form new AI-driven collaboration worth over USD 1.7b
US-based Iambic Therapeutics and Japanese pharmaceutical giant Takeda Pharmaceutical Co. (TSE: 4502) announced a multi-year technology and discovery collaboration to design and…
Cullgen enters NTRK-targeted degrader CG001419 into the clinic
Cullgen (Shanghai), Inc. has initiated a first-in-human (FIH) Phase I/II clinical trial (NCT07394374) to evaluate CG001419, an investigational oral therapy for patients…
BioNTech initiates first-in-human Phase I Trial for HIV antibody BNT351
BioNTech SE has launched a first-in-human (FIH) Phase I clinical trial (NCT07392372) to evaluate the safety, pharmacokinetics, and antiviral activity of BNT351,…
GSK takes EC approval for Nucala as first biologic for eosinophilic COPD
The European Commission (EC) has approved Nucala (mepolizumab), a monoclonal antibody developed by GSK, as an add-on maintenance treatment for adults with…
Priovant posts breakthrough Phase II data for brepocitinib in cutaneous sarcoidosis
Priovant Therapeutics announced positive results from its Phase II BEACON study evaluating brepocitinib, a dual selective inhibitor of TYK2 and JAK1, in…
SpyGlass Pharma prices USD 150m IPO to fuel late-stage ophthalmic pipeline
California-based SpyGlass Pharma, Inc. (Nasdaq: SGP), a specialist in ocular drug delivery, announced the pricing of its initial public offering (IPO). The…
Bayer’s FXIa inhibitor adundexian hits OCEANIC-STROKE endpoints
Bayer announced positive results from the Phase III OCEANIC-STROKE trial evaluating asundexian, an investigational oral Factor XIa (FXIa) inhibitor, in patients following…
US FDA hands Priority Review to Pfizer’s Hympavzi sBLA in two hemophilia populations
Pfizer Inc. (New York, NY) announced that the US FDA has accepted for filing a supplemental Biologics License Application (sBLA) and granted…
LB Pharmaceuticals secures USD 100m funding for neuropsychiatric pipeline
LB Pharmaceuticals Inc., (Nasdaq: LBRX) announced a securities purchase agreement for a private placement expected to yield gross proceeds of approximately USD…
Partner, Merus pick up ODD for zenocutuzumab in NRG1-positive cholangiocarcinoma
The US FDA awarded Orphan Drug Designation to zenocutuzumab-zbco (Bizengri) for treating adults with advanced unresectable or metastatic cholangiocarcinoma harboring a NRG1…
Merck partner Kelun-Biotech gets new indication in China for TROP-2 ADC Sac-TMT in HR+/HER2- mBC
The China National Medical Products Administration (NMPA) issued a new indication approval for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd’s TROP-2-targeted antibody drug conjugate…
AIM ImmunoTech’s reports positive Phase II for Ampligen + Imfinzi in pancreatic cancer
US-based AIM ImmunoTech announced positive interim results from its Phase II clinical trial evaluating a combination immunotherapy approach for metastatic pancreatic cancer.…
Veradermics raises USD 256m via NYSE listing
Connecticut-based dermatology-focused biotech Veradermics held an initial public offering (IPO) to the New York Stock Exchange (ticker: MANE), releasing just over 15…
The AllSci Brief
Systematic R&D and deal news. Daily.